Largest Healthcare Companies by Country 2026

Global Healthcare Master List | Updated August 2026

Which are the largest healthcare companies in the world in 2026? This master database tracks major healthcare companies with approximately US$1 billion or more in annual or trailing-twelve-month revenue, grouped by country and healthcare sector.

Unlike traditional pharmaceutical rankings, this database covers the entire healthcare ecosystem — pharmaceuticals, biotechnology, hospitals, healthcare services, medical devices, diagnostics, contract research, CDMOs, pharmaceutical distribution and healthcare insurance.

US$1B+ Revenue inclusion threshold

8 Healthcare sectors

200+ Target companies

30+ Countries represented

What counts as a healthcare company?

A company is included when healthcare is a material part of its business and its latest reported annual or TTM revenue is approximately US$1 billion or more. Companies are classified by their principal business model rather than being treated as interchangeable healthcare businesses.

Contents

1. Healthcare Industry Taxonomy
2. Global Healthcare Revenue Leaders
3. United States
4. China
5. Switzerland
6. Japan
7. United Kingdom
8. Germany
9. France
10. Denmark
11. India
12. Malaysia
13. Singapore
14. South Korea
15. Canada
16. Australia
17. Italy
18. Spain
19. Belgium
20. Israel
21. Sweden
22. Other Countries
23. Healthcare Sector Breakdown
24. Investor Framework
25. Methodology
26. FAQ

1. The Global Healthcare Industry Taxonomy

The global healthcare industry is much larger than pharmaceutical and biotechnology companies alone.

For this database, companies are classified into eight major sectors.

• Pharmaceuticals: innovative medicines, specialty pharmaceuticals and generic medicines.
• Biotechnology: biologics, cell therapy, gene therapy, RNA therapeutics and other biotechnology-driven medicines.
• Hospitals & Health Systems: hospital groups, private hospital networks and integrated healthcare systems.
• Healthcare Services: diagnostics, outpatient care, ambulatory care and other provider services.
• Medical Devices & MedTech: medical devices, surgical equipment, cardiovascular devices, diabetes technology and diagnostics equipment.
• CRO/CDMO & Life Sciences: contract research, drug development, pharmaceutical manufacturing and biologics manufacturing.
• Healthcare Distribution: pharmaceutical wholesalers and healthcare supply-chain companies.
• Healthcare Payers: health insurance, managed care and healthcare-benefit companies.

2. Global Healthcare Revenue Leaders 2026

Revenue rankings change depending on whether insurers, distributors and pharmaceutical companies are combined. A broad healthcare ranking therefore needs to identify the business model rather than simply sorting companies into one undifferentiated list.

Rank	Company	Country	Sector	Approx. Revenue	Ticker
1	UnitedHealth Group	USA	Healthcare Payer	US$450.1B TTM	UNH
2	CVS Health	USA	Payer / Pharmacy / Services	US$407.9B TTM	CVS
3	McKesson	USA	Healthcare Distribution	US$403.4B TTM	MCK
4	Cencora	USA	Healthcare Distribution	US$328.7B TTM	COR
5	Cigna	USA	Healthcare Payer	US$277.9B TTM	CI
6	Cardinal Health	USA	Healthcare Distribution	US$250.6B TTM	CAH
7	Elevance Health	USA	Healthcare Payer	US$201.1B TTM	ELV
8	Centene	USA	Healthcare Payer	US$198.1B TTM	CNC
9	Humana	USA	Healthcare Payer	US$137.2B TTM	HUM
10	Johnson & Johnson	USA	Pharma / MedTech	~US$99B TTM	JNJ
11	HCA Healthcare	USA	Hospitals	~US$75B	HCA
12	Roche	Switzerland	Pharma / Diagnostics	~US$70–80B	ROG.SW
13	Eli Lilly	USA	Pharmaceuticals	~US$70B+	LLY
14	Merck & Co.	USA	Pharmaceuticals	~US$64B	MRK
15	Pfizer	USA	Pharmaceuticals	~US$63B	PFE
16	AbbVie	USA	Pharmaceuticals	~US$60B+	ABBV
17	AstraZeneca	UK	Pharmaceuticals	~US$60B	AZN
18	Novartis	Switzerland	Pharmaceuticals	~US$55B+	NVS
19	Sanofi	France	Pharmaceuticals	~US$50B+	SNY
20	Novo Nordisk	Denmark	Pharmaceuticals	~US$50B+	NVO / NOVO-B

↔ Swipe the table sideways to see all columns on mobile

3. United States

The United States is the world's deepest healthcare market, spanning pharmaceuticals, biotechnology, hospitals, managed care, medical devices, distribution and healthcare services.

Company	Revenue, Approx.	Ticker	Sector	Primary Focus
UnitedHealth Group	US$450B+	UNH	Payer / Services	Health insurance, Optum
CVS Health	US$400B+	CVS	Payer / Pharmacy	Insurance, pharmacy, healthcare services
McKesson	US$400B+	MCK	Distribution	Pharmaceutical distribution
Cencora	US$325B+	COR	Distribution	Pharmaceutical distribution
Cigna	US$275B+	CI	Payer	Health insurance / services
Cardinal Health	US$250B+	CAH	Distribution	Pharmaceutical distribution
Elevance Health	US$200B+	ELV	Payer	Health insurance
Centene	US$195B+	CNC	Payer	Managed healthcare
Humana	US$135B+	HUM	Payer	Medicare / healthcare services
Johnson & Johnson	~US$99B	JNJ	Pharma / MedTech	Oncology, immunology, surgery
HCA Healthcare	~US$75B	HCA	Hospitals	Hospital network
Merck & Co.	~US$64B	MRK	Pharma	Oncology, vaccines
Pfizer	~US$63B	PFE	Pharma	Vaccines, oncology
AbbVie	~US$60B+	ABBV	Pharma	Immunology, oncology
Eli Lilly	~US$70B+	LLY	Pharma	Diabetes, obesity, oncology
Bristol Myers Squibb	~US$48B	BMY	Pharma	Oncology, immunology
Amgen	~US$37B	AMGN	Biotech	Oncology, inflammation
Gilead Sciences	~US$30B	GILD	Biotech	HIV, oncology, liver disease
Thermo Fisher Scientific	~US$43B	TMO	Life Sciences	Research tools, diagnostics
Abbott Laboratories	~US$44B	ABT	MedTech	Diagnostics, cardiovascular, diabetes
Medtronic	~US$34B	MDT	MedTech	Cardiovascular, surgical devices
Stryker	~US$25B	SYK	MedTech	Orthopedics, surgical equipment
Danaher	~US$24B	DHR	Life Sciences / Diagnostics	Diagnostics, biotechnology tools
Boston Scientific	~US$18B	BSX	MedTech	Cardiovascular, endoscopy
Regeneron	~US$14B	REGN	Biotech	Immunology, oncology
Vertex Pharmaceuticals	~US$12B	VRTX	Biotech	Genetic disease
Viatris	~US$15B	VTRS	Pharma	Generics, biosimilars
GE HealthCare	~US$20B	GEHC	MedTech	Medical imaging, diagnostics
IQVIA	~US$16B	IQV	CRO / Services	Clinical research, data
Labcorp	~US$13B	LH	Diagnostics	Laboratory services
Quest Diagnostics	~US$11B	DGX	Diagnostics	Laboratory testing
Organon	~US$6B	OGN	Pharma	Women's health, biosimilars
Incyte	~US$5B	INCY	Biotech	Oncology, immunology
Alnylam Pharmaceuticals	~US$4B	ALNY	Biotech	RNA interference
BioMarin	~US$3B	BMRN	Biotech	Rare disease
Moderna	~US$2B	MRNA	Biotech	mRNA medicines
Medpace	~US$2.8B guidance	MEDP	CRO	Clinical trials

↔ Swipe the table sideways to see all columns on mobile

4. China

Company	Revenue, Approx.	Ticker	Sector	Focus
Sinopharm Group	US$80B+	1099.HK	Distribution / Pharma	Healthcare distribution
China Resources Pharmaceutical	US$35B+	3320.HK	Pharma / Distribution	Pharmaceuticals
Shanghai Pharmaceuticals	US$35B+	601607.SH	Pharma / Distribution	Pharmaceuticals
Guangzhou Baiyunshan	US$10B+	600332.SH	Pharma	Traditional and modern medicine
WuXi AppTec	US$6B+	2359.HK	CRO/CDMO	Drug development
WuXi Biologics	US$3B+	2269.HK	CDMO	Biologics manufacturing
Fosun Pharma	~US$6B	600196.SH	Pharma	Oncology, vaccines
Jiangsu Hengrui Medicine	~US$4B+	600276.SH	Pharma	Oncology, immunology
CSPC Pharmaceutical	~US$4B	1093.HK	Pharma	Oncology, CNS
Sino Biopharmaceutical	~US$4B	1177.HK	Pharma	Oncology, liver disease
Hansoh Pharmaceutical	~US$2B	3692.HK	Pharma	Oncology, CNS
Innovent Biologics	~US$2B	1801.HK	Biotech	Oncology, immunology
BeiGene / BeOne Medicines	~US$4B+	ONC	Biotech	Oncology
Huadong Medicine	~US$6B	000963.SZ	Pharma	Metabolic, oncology

↔ Swipe the table sideways to see all columns on mobile.

5. Switzerland

Company	Revenue	Ticker	Sector	Focus
Roche	~US$70–80B	ROG.SW	Pharma / Diagnostics	Oncology, immunology
Novartis	~US$55B+	NOVN.SW	Pharma	Oncology, cardiovascular
Sandoz	~US$11B	SDZ.SW	Generics / Biosimilars	Generics
Lonza	~US$8B	LONN.SW	CDMO	Biologics manufacturing
Galderma	~US$5B	GALD.SW	Dermatology	Medical aesthetics, dermatology
Siegfried	~US$1.7B	SFZN.SW	CDMO	Pharmaceutical manufacturing

6. Japan

Company	Revenue	Ticker	Sector	Focus
Takeda Pharmaceutical	~US$30B	TAK	Pharma	GI, oncology, rare disease
Otsuka Holdings	~US$14B	4578.T	Pharma	CNS, oncology
Astellas Pharma	~US$10B+	4503.T	Pharma	Oncology, immunology
Daiichi Sankyo	~US$10B+	4568.T	Pharma	Oncology, ADCs
Chugai Pharmaceutical	~US$7B	4519.T	Pharma	Oncology, immunology
Eisai	~US$5B	4523.T	Pharma	Neurology, oncology
Ono Pharmaceutical	~US$3B+	4528.T	Pharma	Oncology
Kyowa Kirin	~US$3B	4151.T	Biotech / Pharma	Rare disease
Shionogi	~US$3B	4507.T	Pharma	Infectious disease
Santen Pharmaceutical	~US$2B	4536.T	Pharma	Ophthalmology

7. United Kingdom

Company	Revenue	Ticker	Sector	Focus
AstraZeneca	~US$60B	AZN	Pharma	Oncology, respiratory
GSK	~US$40B+	GSK	Pharma / Vaccines	Vaccines, respiratory, HIV
Hikma Pharmaceuticals	~US$3B+	HIK	Pharma	Generics, injectables
Smith & Nephew	~US$6B	SN.L	MedTech	Orthopedics, wound care
Royalty Pharma	~US$2B+	RPRX	Biopharma Finance	Drug royalties

8. Germany

Company	Revenue	Ticker	Sector	Focus
Bayer	~US$50B+	BAYN.DE	Pharma / Healthcare	Cardiovascular, oncology
Merck KGaA	~US$25B	MRK.DE	Pharma / Life Sciences	Pharma, laboratory technology
Fresenius	~US$25B	FRE.DE	Healthcare Services	Hospitals, medical products
Fresenius Medical Care	~US$20B	FMS	Healthcare Services	Dialysis
BioNTech	~US$3B	BNTX	Biotech	mRNA, oncology

9. France

Company	Revenue	Ticker	Sector	Focus
Sanofi	~US$50B+	SNY	Pharma / Vaccines	Immunology, vaccines
Ipsen	~US$4B+	IPN.PA	Pharma	Oncology, rare disease
Virbac	~US$1.7B	VIRP.PA	Animal Health	Veterinary medicine
bioMérieux	~US$4B	BIM.PA	Diagnostics	Clinical diagnostics

10. Denmark

Company	Revenue	Ticker	Sector	Focus
Novo Nordisk	~US$50B+	NVO / NOVO-B	Pharma	Diabetes, obesity
Genmab	~US$3B+	GMAB	Biotech	Antibody oncology
Lundbeck	~US$3B+	HLUN-B.CO	Pharma	Neuroscience
ALK-Abelló	~US$1B+	ALK-B.CO	Biotech	Allergy immunotherapy

11. India

India is one of the world's most important pharmaceutical manufacturing centres and is also developing a rapidly expanding private hospital sector.

Company	Revenue	Ticker	Sector	Focus
Sun Pharmaceutical	~US$6B+	SUNPHARMA.NS	Pharma	Specialty pharma, generics
Aurobindo Pharma	~US$4B	AUROPHARMA.NS	Pharma	Generics, APIs
Dr. Reddy's Laboratories	US$3.58B FY2026	RDY	Pharma	Generics, APIs
Zydus Lifesciences	~US$3B	ZYDUSLIFE.NS	Pharma	Generics, vaccines
Cipla	~US$3B	CIPLA.NS	Pharma	Respiratory, generics
Lupin	~US$3B	LUPIN.NS	Pharma	Generics, respiratory
Biocon	~US$2B	BIOCON.NS	Biotech	Biologics, biosimilars
Glenmark Pharmaceuticals	~US$2B	GLENMARK.NS	Pharma	Specialty medicine
Alkem Laboratories	~US$1.6B	ALKEM.NS	Pharma	Generics
Mankind Pharma	~US$1.5B	MANKIND.NS	Pharma	Generics / consumer health
Torrent Pharmaceuticals	~US$1.5B	TORNTPHARM.NS	Pharma	Cardiology, CNS
Divi's Laboratories	~US$1.2B	DIVISLAB.NS	CDMO / APIs	Pharmaceutical ingredients
Apollo Hospitals	~US$3B+	APOLLOHOSP.NS	Hospitals	Hospitals, pharmacy
Fortis Healthcare	~US$1B+	FORTIS.NS	Hospitals	Private hospitals
Max Healthcare	~US$1B+	MAXHEALTH.NS	Hospitals	Private hospitals
Manipal Health	~US$1B+	Private	Hospitals	Hospital network

↔ Swipe the table sideways to see all columns on mobile

12. Malaysia

Company	Revenue	Ticker	Sector	Primary Business
IHH Healthcare Berhad	FY2025 ~US$6B+	5225	Hospitals / Healthcare Services	Private hospitals, diagnostics and healthcare services
KPJ Healthcare Berhad	FY2025 ~US$1B+	5878	Hospitals	Private hospitals and specialist healthcare
Duopharma Biotech	~US$0.5–1B	KLSE: DPHARMA	Pharma	Generics and consumer healthcare
Pharmaniaga	~US$0.5–1B	7081	Pharma / Distribution	Pharmaceutical manufacturing and distribution

↔ Swipe the table sideways to see all columns on mobile

Malaysia threshold note: IHH and KPJ clearly qualify under the US$1B screening threshold based on reported FY2025 revenue. Smaller Malaysian healthcare companies should be tracked in the extended database even when they are currently below US$1B, rather than being incorrectly presented as qualifying companies.

13. Singapore

Company	Revenue	Ticker	Sector	Focus
Raffles Medical Group	~US$0.6–1B	BSL.SI	Healthcare Services	Hospitals and clinics
Healthway Medical	~US$0.1B	5NG.SI	Healthcare Services	Primary healthcare

Singapore is also strategically important because major multinational healthcare groups operate substantial businesses there, including IHH Healthcare through its Parkway and Mount Elizabeth operations.

14. South Korea

Company	Revenue	Ticker	Sector	Focus
Samsung Biologics	US$4B+	207940.KS	CDMO	Biologics manufacturing
Celltrion	US$3B+	068270.KS	Biotech	Biosimilars
Yuhan	~US$1.5B	000100.KS	Pharma	Oncology, specialty pharma
Hanmi Pharmaceutical	~US$1B+	128940.KS	Pharma	Oncology, metabolic disease

15. Canada

Company	Revenue	Ticker	Sector	Focus
Bausch Health	~US$10B+	BHC	Pharma	Specialty pharmaceuticals
Vancouver Coastal / Major Health Systems	Varies	Private/Public	Hospitals	Healthcare services
Apotex	>$1B	Private	Pharma	Generics

16. Australia

Company	Revenue	Ticker	Sector	Focus
CSL	~US$15B	CSL.AX	Biotech	Plasma, vaccines
Ramsay Health Care	~US$10B+	RHC.AX	Hospitals	Private hospitals
ResMed	~US$4B	RMD	MedTech	Sleep medicine
Sonic Healthcare	~US$6B	SHL.AX	Diagnostics	Pathology and diagnostics

17. Italy

Company	Revenue	Ticker	Sector	Focus
Recordati	~US$3B	REC.MI	Pharma	Rare disease, specialty pharma
Chiesi Farmaceutici	Several US$B	Private	Pharma	Respiratory, rare disease
Menarini Group	Several US$B	Private	Pharma	Specialty pharmaceuticals

18. Spain

Company	Revenue	Ticker	Sector	Focus
Grifols	~US$8B+	GRF.MC	Biotech	Plasma-derived medicines
Almirall	~US$1.5B	ALM.MC	Pharma	Dermatology

19. Belgium

Company	Revenue	Ticker	Sector	Focus
UCB	~US$8B+	UCB.BR	Biotech / Pharma	Immunology, neurology
Galapagos	~US$1B+	GLPG	Biotech	Immunology

20. Israel

Company	Revenue	Ticker	Sector	Focus
Teva Pharmaceutical Industries	~US$17B	TEVA	Pharma	Generics, specialty medicine

21. Sweden

Company	Revenue	Ticker	Sector	Focus
Sobi	~US$3B	SOBI.ST	Biotech	Rare disease
Elekta	~US$1.5B	EKTA-B.ST	MedTech	Radiation oncology
Getinge	~US$3B	GETI-B.ST	MedTech	Surgical and ICU equipment

22. Additional Global Healthcare Companies

The following companies should be incorporated into the extended database. Some are clearly above the US$1B threshold, while borderline companies should be rechecked against their latest annual or TTM revenue before publication.

Country	Company	Sector	Approx. Revenue
Netherlands	Philips	MedTech	US$18B+
Netherlands	Qiagen	Diagnostics	US$2.5B+
Netherlands	Merus	Biotech	Below/around threshold
Ireland	Jazz Pharmaceuticals	Biotech / Pharma	US$4B+
Ireland	Horizon Therapeutics / Amgen operations	Pharma	Integrated
Austria	Octapharma	Biotech	Several US$B
Austria	Takeda Austrian operations	Pharma	Integrated
Norway	Orkla Health	Healthcare / Consumer	US$1B+
Finland	Orion	Pharma	US$2B+
Hungary	Gedeon Richter	Pharma	US$2B+
South Africa	Aspen Pharmacare	Pharma	US$2B+
Turkey	Acibadem Healthcare Group	Hospitals	US$1B+
Turkey	Roche Turkey	Pharma	Subsidiary
Brazil	Hypera Pharma	Pharma	US$1B+
Brazil	Rede D'Or	Hospitals	US$2B+
Mexico	Genomma Lab	Healthcare / Consumer	US$1B+
Argentina	Roemmers	Pharma	US$1B+
Thailand	Bangkok Dusit Medical Services	Hospitals	US$3B+
Thailand	BDMS	Hospitals	US$3B+
Thailand	Thai Otsuka	Pharma	Subsidiary
Indonesia	Kalbe Farma	Pharma / Healthcare	US$1B+
Indonesia	Mitra Keluarga	Hospitals	US$0.5–1B
Philippines	Metro Pacific Health	Hospitals	US$1B+ group scale
Saudi Arabia	Mouwasat Medical Services	Hospitals	US$1B+
Saudi Arabia	Dr. Sulaiman Al Habib Medical Services	Hospitals	US$2B+
UAE	Burjeel Holdings	Hospitals	US$1B+

23. The Eight Healthcare Sectors

1. Pharmaceuticals

The pharmaceutical sector includes traditional Big Pharma, specialty pharmaceutical companies and large generic-drug manufacturers.

Major examples include Eli Lilly, Merck, Pfizer, Roche, Novartis, AstraZeneca, Sanofi, Novo Nordisk, Takeda, Teva and Sun Pharma.

2. Biotechnology

Biotechnology companies increasingly overlap with pharmaceutical companies. The distinction in this database is based on business identity and technology rather than simply company size.

Important examples include Amgen, Regeneron, Vertex, Gilead, BioNTech, Moderna, Biocon, CSL, Celltrion and Genmab.

3. Hospitals & Health Systems

Hospital groups are now an essential component of the global healthcare economy.

Examples include HCA Healthcare, IHH Healthcare, KPJ Healthcare, Apollo Hospitals, Ramsay Health Care, Fresenius, Fortis Healthcare, Max Healthcare, Bangkok Dusit Medical Services and Rede D'Or.

4. Healthcare Services

This category includes diagnostics, laboratories, outpatient care, ambulatory healthcare and other healthcare delivery platforms.

5. Medical Devices & MedTech

Medical technology companies include Abbott, Medtronic, Stryker, Boston Scientific, GE HealthCare, Philips, ResMed, Smith & Nephew and Getinge.

6. CRO, CDMO & Life Sciences

Modern pharmaceutical development depends heavily on companies such as IQVIA, Thermo Fisher, WuXi AppTec, WuXi Biologics, Lonza and other contract research and manufacturing organizations.

7. Healthcare Distribution

Distribution companies can generate enormous revenue because they operate large-volume, low-margin pharmaceutical supply chains.

Examples include McKesson, Cencora, Cardinal Health and Sinopharm.

8. Healthcare Payers

Healthcare insurers and managed-care companies are included because they represent a major component of healthcare spending.

Examples include UnitedHealth Group, CVS Health, Cigna, Elevance Health, Centene and Humana.

24. Revenue Is Not the Same as Market Capitalization

A central feature of this database is the separation of revenue from market capitalization.

• Revenue measures the scale of the business.
• Market capitalization reflects the market value assigned to a public company.
• Enterprise value incorporates debt and cash.
• Profitability shows how efficiently revenue is converted into earnings.
• Free cash flow provides another measure of financial quality.

A hospital operator, pharmaceutical company and healthcare insurer can have similar revenue but completely different margins, capital intensity, competitive advantages and valuation.

25. How Investors Should Analyse Healthcare Companies

Revenue should be considered the first screening layer rather than the final investment criterion.

1. Revenue growth: Is the company gaining or losing market share?
2. Profit margins: How much profit is generated from each dollar of revenue?
3. Free cash flow: Can the business fund expansion and return capital to shareholders?
4. R&D productivity: Is research producing commercially successful products?
5. Patent exposure: Are important drugs approaching patent expiry?
6. Pipeline: What future products could replace declining revenue?
7. Regulatory risk: Could regulation materially change the economics?
8. Debt: Is leverage appropriate for the business model?
9. Valuation: What price is the market paying for future earnings?
10. Competitive advantage: Does the company possess intellectual property, scale, distribution, clinical expertise or network effects?

26. Major Healthcare Investment Themes for 2026

The global healthcare industry is being reshaped by several major trends.

Obesity GLP-1 Oncology Immunotherapy Antibody-Drug Conjugates Radiopharmaceuticals Cell Therapy Gene Therapy RNA Medicines AI Drug Discovery Biosimilars Diagnostics Hospital Expansion Precision Medicine

Obesity and Metabolic Medicine

GLP-1 and related metabolic therapies have become one of the most important commercial growth areas in global healthcare, particularly for Novo Nordisk and Eli Lilly.

Oncology

Cancer remains one of the largest pharmaceutical markets, with major investment in immunotherapy, targeted therapy, antibody-drug conjugates, bispecific antibodies and radiopharmaceuticals.

AI and Healthcare

Artificial intelligence is increasingly being applied to drug discovery, clinical trials, diagnostics, medical imaging, hospital operations and healthcare administration.

Hospital Consolidation

Private hospital networks continue to expand through new facilities, acquisitions, specialist centres and higher-acuity medical services. Apollo's 2026 expansion plans, for example, include thousands of additional hospital beds, demonstrating the scale of the private healthcare growth opportunity in emerging markets.

27. Methodology & Data Definitions

Revenue threshold: approximately US$1 billion.

Revenue period: latest available annual or trailing-twelve-month revenue during 2026.

Currency: local-currency revenue is converted to US dollars for comparison.

Country: normally headquarters or principal corporate domicile. Operational footprint may extend across multiple countries.

Public/private: public companies receive a stock ticker where applicable. Private companies are identified separately.

Market capitalization: market cap is intentionally treated as a separate, date-sensitive field. It should be refreshed before every investment-oriented update.

Important: Healthcare companies report on different fiscal calendars and use different accounting structures. TTM revenue, fiscal-year revenue and constant-currency revenue should not be treated as perfectly interchangeable.

28. Frequently Asked Questions

What is the largest healthcare company in the world by revenue?

The answer depends on the definition of healthcare. When insurers, healthcare distributors and pharmaceutical companies are combined, UnitedHealth Group is among the largest, with TTM revenue above US$450 billion in mid-2026.

Why include hospitals in a pharmaceutical ranking?

This article is no longer a pharmaceutical-only ranking. It is a global healthcare-company database. Hospitals are therefore classified as a separate healthcare sector.

Why are healthcare distributors included?

Companies such as McKesson, Cencora and Cardinal Health generate enormous revenue by distributing medicines and healthcare products. Their margins and business models differ substantially from pharmaceutical manufacturers, so they are classified separately.

Why are insurers included?

Healthcare insurers and managed-care companies represent a major part of healthcare spending and are therefore included in the broad healthcare database as the payer category.

Does revenue determine the best healthcare investment?

No. Revenue measures business scale, not investment quality. Growth, profitability, cash flow, valuation, competitive advantage, pipeline quality, regulatory risk and balance-sheet strength should also be considered.

29. Bottom Line

The global healthcare industry is much larger than Big Pharma.

The most useful 2026 framework is therefore not simply “largest pharma companies”, but “largest healthcare companies.”

The ecosystem includes pharmaceutical companies such as Eli Lilly and Roche; biotechnology companies such as Amgen and Vertex; hospital groups such as HCA, IHH and KPJ; medical-device leaders such as Abbott and Medtronic; healthcare distributors such as McKesson and Cencora; CRO/CDMOs such as IQVIA and Lonza; diagnostics companies such as Labcorp; and healthcare payers such as UnitedHealth and Cigna.

This broader structure also makes country comparisons considerably more meaningful. The United States dominates across multiple healthcare sectors, Switzerland has extraordinary pharmaceutical concentration, China and Japan have deep pharmaceutical ecosystems, India combines pharma manufacturing with rapidly expanding hospital networks, and Malaysia has emerging regional champions such as IHH Healthcare and KPJ Healthcare.

OneDayAdvisor Healthcare Intelligence Framework:

Use this page as the global master index. Individual country pages, pharmaceutical-sector pages, biotech pages, hospital-group rankings, MedTech rankings and healthcare-investment themes can then link back to this master pillar.

Related: Largest Pharma & Biotech Companies by Country 2026

Data disclaimer: Revenue figures are rounded and may represent the latest annual or TTM period available during 2026. Fiscal periods differ between companies. Exchange rates affect USD conversions. Market capitalization changes daily. This database is intended for research and educational purposes and is not investment advice.